A study published in JAMA
indicates that treatment with bright light alone (1,000 lux), or
bright light combined with melatonin,
can improve symptoms in patients with dementia. Melatonin
alone appeared to have a slight adverse effect.
This already has been reported by Time,
News Today. As I start to write it, though, I can
find only one
blog that mentions it, so it is worth mentioning here.
This was a long-term study of a medium number of elderly patients with
dementia, all of whom lived in a group setting. It
was a randomized, double-blind study. Specifically, it
included 189 patients who were followed for a mean of 15 months.
The effect size was not great, but it was statistically significant.
Moreover, there were improvements in mood, functional, and
behavioral measures. Cognitive function on the Mini-Mental
State Exam (a measure of cognitive function) declined by 0.9
points less in the group that received bright light. Scores
on the Cornell
Scale for Depression in Dementia were better by 19%.
Bright light also reduced the increase in functional
limitations over time by 1.8 points per year on the Nurse-informant
Activities of Daily Living Scale (a relative 53% difference).
Combined treatment reduced aggressive behavior by 9%
on the Cohen-Mansfield
of Bright Light and Melatonin on Cognitive and Noncognitive Function in
Elderly Residents of Group Care Facilities
Rixt F. Riemersma-van der Lek, MD; Dick F. Swaab, MD,
PhD; Jos Twisk, PhD; Elly M. Hol, PhD; Witte J. G. Hoogendijk, MD, PhD;
Eus J. W. Van Someren, PhD
decline, mood, behavioral and sleep disturbances, and limitations of
activities of daily living commonly burden elderly patients with
dementia and their caregivers. Circadian rhythm disturbances have been
associated with these symptoms.
Objective To determine whether the
progression of cognitive and noncognitive symptoms may be ameliorated
by individual or combined long-term application of the 2 major
synchronizers of the circadian timing system: bright light and
Design, Setting, and Participants A
long-term, double-blind, placebo-controlled, 2 x 2 factorial randomized
trial performed from 1999 to 2004 with 189 residents of 12 group care
facilities in the Netherlands; mean (SD) age, 85.8 (5.5) years; 90%
were female and 87% had dementia.
Interventions Random assignment by
facility to long-term daily treatment with whole-day bright (± 1000
lux) or dim (± 300 lux) light and by participant to evening melatonin
(2.5 mg) or placebo for a mean (SD) of 15 (12) months (maximum period
of 3.5 years).
Main Outcome Measures Standardized
scales for cognitive and noncognitive symptoms, limitations of
activities of daily living, and adverse effects assessed every 6 months.
Results Light attenuated cognitive
deterioration by a mean of 0.9 points (95% confidence interval [CI],
0.04-1.71) on the Mini-Mental State Examination or a relative 5%. Light
also ameliorated depressive symptoms by 1.5 points (95% CI, 0.24-2.70)
on the Cornell Scale for Depression in Dementia or a relative 19%, and
attenuated the increase in functional limitations over time by 1.8
points per year (95% CI, 0.61-2.92) on the nurse-informant activities
of daily living scale or a relative 53% difference. Melatonin shortened
sleep onset latency by 8.2 minutes (95% CI, 1.08-15.38) or 19% and
increased sleep duration by 27 minutes (95% CI, 9-46) or 6%. However,
melatonin adversely affected scores on the Philadelphia Geriatric
Centre Affect Rating Scale, both for positive affect (-0.5 points; 95%
CI, -0.10 to -1.00) and negative affect (0.8 points; 95% CI,
0.20-1.44). Melatonin also increased withdrawn behavior by 1.02 points
(95% CI, 0.18-1.86) on the Multi Observational Scale for Elderly
Subjects scale, although this effect was not seen if given in
combination with light. Combined treatment also attenuated aggressive
behavior by 3.9 points (95% CI, 0.88-6.92) on the Cohen-Mansfield
Agitation Index or 9%, increased sleep efficiency by 3.5% (95% CI,
0.8%-6.1%), and improved nocturnal restlessness by 1.00 minute per hour
each year (95% CI, 0.26-1.78) or 9% (treatment x time effect).
Conclusions Light has a modest benefit
in improving some cognitive and noncognitive symptoms of dementia. To
counteract the adverse effect of melatonin on mood, it is recommended
only in combination with light.
Note that no one is saying that the treatment(s) had any effect on the
underlying disease process. Rather, the treatment(s) had an
effect on symptoms. Even so, the findings are clinically
important. Specifically, the reduction in aggression, and the
slower decline in loss of ADL function, could improve quality of life.
Those differences also could reduce caregiver burden.
There are limitations to the study. Owing to the nature of
the population being studied, there was a lot of missing data.
People died, or transferred to other facilities.
Some facilities stopped participating. There are
statistical ways of adjusting for this, but is still is a limitation.
Also, the study was carried out in the Netherlands.
This is not a flaw or limitation, per se, but it may affect
the generalizability of the outcome. Amsterdam is at latitude
52°N, as compared to, say, New York City, at 40°N, or Mexico City at
19°N. Would the effect be the same in a less northern
location? Probably, since the indoor lighting conditions may
not be that much different; but, you don’t know until you do the study.
Of course the biggest limitation is that studies such as these need to
be replicated elsewhere, before any firm conclusion can be drawn.
So what is going on in the brain? Ageing is known to affect
the function of the circadian timing system (biological clock) in the
part of the brain known as the suprachiasmatic
nucleus. Melatonin and bright light help to correct
the alterations in this functioning. It is not clear how this
improves cognitive function, aggressive behavior, and activities of
daily living. The positive effect on mood is understood a
little better, as Coturnix
In vague terms, it seems likely that boosting the function of the
circadian timing system helps to optimize a variety of physiological
functions. This may be how the treatment helps with the other
symptoms. This explanation is not very helpful, though, as it
does not explain the divergence in findings between melatonin alone,
bright light alone, and combined treatment. Like most of
these studies, it generates a lot more questions than it answers.
There are a few more interesting points to consider. Note
that bright light and melatonin both are inexpensive. The
benefits from these interventions are comparable
in size to those seen from patented (expensive) medications.
Plus, if the caregiver burden is decreased, the cost of
providing care could actually go down, while the quality of life goes
up. It’s hard to beat that, from a cost-effectiveness